跳至主要内容
临床试验/NCT06560385
NCT06560385尚未招募不适用

A Pilot, Double-blind, Randomised, Placebo-controlled Trial on the Efficacy of a Synbiotic Formula (BLHK03) in Alleviating Chemotherapy-induced Alopecia (CIA) in Breast Cancer Patients

GenieBiome Limited2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年8月19日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40
试验地点
2
主要终点
The proportion of subjects with a score of ≤ 2 on the Dean scale (corresponding to hair loss ≤ 50%) 2 months after the final dose of chemotherapy

研究概览

简要总结

This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.

详细描述

In a mice study, it was shown that oral administration of a probiotic isolated from healthy faeces, B. longum HK003, has protective effects against alopecia related to chemotherapy. Mice were treated with 100 mg/kg cyclophosphamide (CYP) once monthly, for 4 months. The CYP-treated mice were then treated with B. longum HK003 for 14 days. Results showed that B. longum treatment significantly enhanced skin thickness histologically. In the subcutis, the quantity and size of anagen follicles were increased, whilst the quantity of atrophic follicles were decreased.

Currently, there is no documentation of potential probiotic-drug interactions in breast cancer patients undergoing chemotherapy. A previous randomized controlled trial reported no adverse event associated with the use of synbiotics in breast cancer patients during the treatment period(9). Beneficial effects on chemotherapy-induced fatigue and abnormal stool consistency were also observed in subjects receiving synbiotics(9).

Biotin is a water-soluble vitamin that is naturally present in some food and available as a dietary supplement for healthy hair and nails due to its role in keratin production. Most healthy individuals achieve adequate intake of biotin through a well-balanced diet. Current recommendation for biotin by the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine stated that the daily adequate intake (AI) for adults is 30 mcg/day. Although biotin has been widely used as dietary supplement, data on the actual benefit of its effect on hair growth is limited(10).

The use of B. longum HK003 in alleviating chemotherapy-induced alopecia in breast cancer patients has not been explored. This pilot, double-blind, randomised, placebo-controlled trial aims to explore on the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

盲法说明

Attending physicians, investigators performing assessments in clinic visits and study participants will be blinded to the group allocation until study completion.

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer
  • Planned chemotherapy including an anthracycline or taxane to be completed within 6 months
  • Mentally capable to participate in the study and provide informed consent

排除标准

  • Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline
  • History of hair transplantation, psoriasis or severe scalp infection
  • Undergoing or plan to receive scalp cooling
  • Plan for immunotherapy
  • Known pregnancy or lactating
  • Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions
  • Use of antibiotics, probiotics or prebiotics one month prior to enrolment
  • No other alternative or complementary treatment for the cancer condition that may affect the gut microbiome analysis
  • History of allergy to probiotics or lactose
  • History of chemotherapy for other conditions

结局指标

主要结局

The proportion of subjects with a score of ≤ 2 on the Dean scale (corresponding to hair loss ≤ 50%) 2 months after the final dose of chemotherapy

时间窗: Baseline to 2 months after the final dose of chemotherapy

The change of Dean scale (corresponding to hair loss) after chemotherapy compared to baseline. Score 0 means no hair loss and score 4 means all hair is fallen down.

次要结局

  • Gut microbial change at 2 months after the final dose of chemotherapy(Baseline to 2 months after the final dose of chemotherapy)
  • Adverse event rates related to the study during the study period(Baseline to 2 months after the final dose of chemotherapy)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验